Triggering receptor expressed on myeloid cells receptor family modulators: A patent review

Christopher J. Pelham, Amit N. Pandya, Devendra K. Agrawal

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Introduction: Triggering receptor expressed on myeloid cells (TREM) receptors and TREM-like transcript (TLT; or TREML) receptors of the immunoglobulin superfamily are known as key modulators of host immune responses. TREM-1 (CD354) and TREM-2 share the transmembrane adaptor DNAX-activation protein of 12 kDa (DAP12), but they possess separate stimulatory and inhibitory functional roles, especially in myeloid cells. Areas covered: This review covers findings related to TREMs and TLTs published in patent applications from their discovery in 2000 to the present. New roles for TREM-1, TREM-2, TLT-1 and TLT-2 in maladies ranging from acute and chronic inflammatory disorders to cardiovascular diseases and cancers are discussed. Putative endogenous ligands and novel synthetic peptide blockers are also discussed. Expert opinion: So far, therapeutic use of activators/blockers specific for TREMs and TLTs has been limited to preclinical animal models. TREM-1 is an immediate therapeutic target for acute and chronic inflammatory conditions, especially sepsis. Certain mutations in DAP12 and TREM-2 manifest into a disorder named polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, and newly identified TREM-2 variants confer a significant increase in risk of developing Alzheimer's disease. This makes TREM-2 an attractive therapeutic target for neurodegenerative diseases.

Original languageEnglish
Pages (from-to)1383-1395
Number of pages13
JournalExpert Opinion on Therapeutic Patents
Volume24
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Myeloid Cells
Expert Testimony
Therapeutic Uses
Neurodegenerative Diseases
Immunoglobulins
Sepsis
Alzheimer Disease
Proteins
Cardiovascular Diseases
Animal Models
Ligands
Peptides
Mutation

All Science Journal Classification (ASJC) codes

  • Drug Discovery
  • Pharmacology
  • Medicine(all)

Cite this

Triggering receptor expressed on myeloid cells receptor family modulators : A patent review. / Pelham, Christopher J.; Pandya, Amit N.; Agrawal, Devendra K.

In: Expert Opinion on Therapeutic Patents, Vol. 24, No. 12, 01.12.2014, p. 1383-1395.

Research output: Contribution to journalReview article

@article{2f819b39f06b4e25be11565972358bcf,
title = "Triggering receptor expressed on myeloid cells receptor family modulators: A patent review",
abstract = "Introduction: Triggering receptor expressed on myeloid cells (TREM) receptors and TREM-like transcript (TLT; or TREML) receptors of the immunoglobulin superfamily are known as key modulators of host immune responses. TREM-1 (CD354) and TREM-2 share the transmembrane adaptor DNAX-activation protein of 12 kDa (DAP12), but they possess separate stimulatory and inhibitory functional roles, especially in myeloid cells. Areas covered: This review covers findings related to TREMs and TLTs published in patent applications from their discovery in 2000 to the present. New roles for TREM-1, TREM-2, TLT-1 and TLT-2 in maladies ranging from acute and chronic inflammatory disorders to cardiovascular diseases and cancers are discussed. Putative endogenous ligands and novel synthetic peptide blockers are also discussed. Expert opinion: So far, therapeutic use of activators/blockers specific for TREMs and TLTs has been limited to preclinical animal models. TREM-1 is an immediate therapeutic target for acute and chronic inflammatory conditions, especially sepsis. Certain mutations in DAP12 and TREM-2 manifest into a disorder named polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, and newly identified TREM-2 variants confer a significant increase in risk of developing Alzheimer's disease. This makes TREM-2 an attractive therapeutic target for neurodegenerative diseases.",
author = "Pelham, {Christopher J.} and Pandya, {Amit N.} and Agrawal, {Devendra K.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1517/13543776.2014.977865",
language = "English",
volume = "24",
pages = "1383--1395",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Triggering receptor expressed on myeloid cells receptor family modulators

T2 - A patent review

AU - Pelham, Christopher J.

AU - Pandya, Amit N.

AU - Agrawal, Devendra K.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Introduction: Triggering receptor expressed on myeloid cells (TREM) receptors and TREM-like transcript (TLT; or TREML) receptors of the immunoglobulin superfamily are known as key modulators of host immune responses. TREM-1 (CD354) and TREM-2 share the transmembrane adaptor DNAX-activation protein of 12 kDa (DAP12), but they possess separate stimulatory and inhibitory functional roles, especially in myeloid cells. Areas covered: This review covers findings related to TREMs and TLTs published in patent applications from their discovery in 2000 to the present. New roles for TREM-1, TREM-2, TLT-1 and TLT-2 in maladies ranging from acute and chronic inflammatory disorders to cardiovascular diseases and cancers are discussed. Putative endogenous ligands and novel synthetic peptide blockers are also discussed. Expert opinion: So far, therapeutic use of activators/blockers specific for TREMs and TLTs has been limited to preclinical animal models. TREM-1 is an immediate therapeutic target for acute and chronic inflammatory conditions, especially sepsis. Certain mutations in DAP12 and TREM-2 manifest into a disorder named polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, and newly identified TREM-2 variants confer a significant increase in risk of developing Alzheimer's disease. This makes TREM-2 an attractive therapeutic target for neurodegenerative diseases.

AB - Introduction: Triggering receptor expressed on myeloid cells (TREM) receptors and TREM-like transcript (TLT; or TREML) receptors of the immunoglobulin superfamily are known as key modulators of host immune responses. TREM-1 (CD354) and TREM-2 share the transmembrane adaptor DNAX-activation protein of 12 kDa (DAP12), but they possess separate stimulatory and inhibitory functional roles, especially in myeloid cells. Areas covered: This review covers findings related to TREMs and TLTs published in patent applications from their discovery in 2000 to the present. New roles for TREM-1, TREM-2, TLT-1 and TLT-2 in maladies ranging from acute and chronic inflammatory disorders to cardiovascular diseases and cancers are discussed. Putative endogenous ligands and novel synthetic peptide blockers are also discussed. Expert opinion: So far, therapeutic use of activators/blockers specific for TREMs and TLTs has been limited to preclinical animal models. TREM-1 is an immediate therapeutic target for acute and chronic inflammatory conditions, especially sepsis. Certain mutations in DAP12 and TREM-2 manifest into a disorder named polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, and newly identified TREM-2 variants confer a significant increase in risk of developing Alzheimer's disease. This makes TREM-2 an attractive therapeutic target for neurodegenerative diseases.

UR - http://www.scopus.com/inward/record.url?scp=84911925679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911925679&partnerID=8YFLogxK

U2 - 10.1517/13543776.2014.977865

DO - 10.1517/13543776.2014.977865

M3 - Review article

C2 - 25363248

AN - SCOPUS:84911925679

VL - 24

SP - 1383

EP - 1395

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 12

ER -